Literature DB >> 9179466

The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care.

C D Agardh1, E Agardh, O Torffvit.   

Abstract

The aim of the present study was to examine mean HbA1c and blood pressure levels during a 5 year period in 442 type 1 adult diabetic patients in relation to the incidence and progression of retinopathy, nephropathy and to cardiovascular morbidity and mortality. The study showed, that in patients under routine care at a diabetic unit with four visits to the out-patient clinic per year, the intraindividual coefficient of variation for HbA1c values was 11 +/- 4% (mean +/- S.D.), and 7 +/- 3 and 8 +/- 2% for systolic and diastolic blood pressure, respectively. In 121 patients without retinopathy at entry, the 5 year incidence of any retinopathy was 47% (n = 57). Patients who developed retinopathy had higher mean HbA1c levels (P < 0.01), as well as mean systolic (P < 0.01) and diastolic (P < 0.05) blood pressure levels. In 123 patients with background retinopathy at entry, progression to severe retinopathy, i.e. clinically significant macular oedema, severe non-proliferative or proliferative retinopathy, occurred in 41% (n = 51). In those patients, the degree of metabolic control was worse (P < 0.001), the systolic (P < 0.05) and diastolic (P < 0.01) blood pressure levels were higher. The patients were stratified into four groups according to their urinary albumin concentration at entry: (1) normal albuminuria (< 12.5 mg/l), (2) borderline albuminuria (12.5-30 mg/l), (3) microalbuminuria (31-299 mg/l), i.c. incipient nephropathy and (4) clinical nephropathy (> or = 300 mg/l). An increase of urinary albumin concentration in patients who had normoalbuminuria or borderline albuminuria at entry was associated with mean HbA1c levels (r = 0.24, P < 0.01 and r = 0.27, P < 0.01, respectively). No such association was seen in patients with microalbuminuria or clinical nephropathy at entry. There was no association between the increase of urinary albumin level and mean systolic blood pressure levels in patients who had normoalbuminuria and microalbuminuria at entry. In contrast, there was an association between the increase of urinary albumin level in patients with borderline albuminuria (r = 0.36, P < 0.001), clinical nephropathy (r = 0.26, P < 0.05) and mean systolic blood pressure (P < 0.05). There was no association between the increase of urinary albumin levels and mean diastolic blood pressure in any of the albuminuria groups. As for the incidence of cardiovascular disease, renal insufficiency or death, the duration of diabetes (P < 0.01), urinary albumin concentration at entry (P < 0.001), mean systolic blood pressure (P < 0.05) and treatment with loop diuretics (P < 0.001) were but age, age at onset of diabetes, mean levels of HbA1c and diastolic blood pressure as well as treatment with beta- or Ca-blockers or ACE inhibitors were not related to these end-points. In conclusion, the present study showed that there was an association between the degree of metabolic control and both development and progression of retinopathy and progression of nephropathy of early stages in type 1 diabetic patients treated under routine conditions. Moreover, both the incidence and progression of retinopathy and progression of nephropathy at later stages were also associated with the long-term blood pressure levels. However, HbA1c levels were not associated with morbidity and mortality in cardiovascular disease or development of renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179466     DOI: 10.1016/s0168-8227(97)01386-7

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  12 in total

1.  Macular circulation in patients with diabetes mellitus with and without arterial hypertension.

Authors:  O Arend; M Rüffer; A Remky
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

2.  Partial resolution of diabetic macular oedema after systemic treatment with furosemide.

Authors:  A P Ciardella
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

3.  Lack of correlation between short-term dynamics of diabetic retinopathy lesions and the arterial blood pressure.

Authors:  Toke Bek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-03       Impact factor: 3.117

4.  Carl-David Agardh, 1946-2013.

Authors:  Leif Groop; Åke Lernmark; Jan Nilsson
Journal:  Diabetologia       Date:  2014-04       Impact factor: 10.122

Review 5.  Choices and goals in the treatment of the diabetic hypertensive patient.

Authors:  E Basta; G Bakris
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 6.  Effect of systemic medications on onset and progression of diabetic retinopathy.

Authors:  Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Lloyd M Aiello; Lloyd Paul Aiello
Journal:  Nat Rev Endocrinol       Date:  2010-07-27       Impact factor: 43.330

7.  The Increased Circulating Plasma Levels of Vascular Endothelial Growth Factor in Patients with Type 1 Diabetes Do Not Correlate to Metabolic Control.

Authors:  Kailash Singh; Stellan Sandler; Daniel Espes
Journal:  J Diabetes Res       Date:  2017-03-21       Impact factor: 4.011

8.  Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study.

Authors:  Patricia Herold Gallego; Maria E Craig; Stephen Hing; Kim C Donaghue
Journal:  BMJ       Date:  2008-08-26

Review 9.  Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic.

Authors:  Philip I Burgess; Gerald Msukwa; Nicholas A V Beare
Journal:  BMC Med       Date:  2013-07-02       Impact factor: 8.775

10.  Personalized risk-based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules.

Authors:  Marta García-Fiñana; David M Hughes; Christopher P Cheyne; Deborah M Broadbent; Amu Wang; Arnošt Komárek; Irene M Stratton; Mehrdad Mobayen-Rahni; Ayesh Alshukri; Jiten P Vora; Simon P Harding
Journal:  Diabetes Obes Metab       Date:  2018-10-30       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.